Global X DAX Germany ETFの空売り状況は、投資家がGlobal X DAX Germany ETFの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Global X DAX Germany ETF (NASDAQ:DAX), 空売り情報

Global X DAX Germany ETF

Industrials

Technology

Financial Services

Consumer Cyclical

Other

Communication Services

Utilities

Basic Materials

Healthcare

Consumer Defensive

Real Estate

The Fund invests at least 80 percent of its total assets in the securities of the DAX Index (DAX Index or Index) and in American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs) based on the securities in the Underlying Index. The Fund's 80 percent investment policy is non-fundamental and requires 60 days prior written notice to shareholders before it can be changed. The Fund's investment objective and Underlying Index may be changed without shareholder approval.

Sap Se

Siemens Ag-reg

Deutsche Telekom Ag-reg

Airbus Se

Mercedes-Benz Group AG

Deutsche Boerse Ag

Deutsche Bank-Rg

Global X Dax Germany ETF

DAEX

Daxor Corp

Results Reinforce the Current Australian Oncology Clinical Trial and Support Investigation of the Hemopurifier Across Multiple Indications
SAN DIEGO, May 14, 2025 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4426889-1&amp;h=3082505802&amp;u=https%3A%2F%2Furl.avanan.click%2Fv2%2F___https%3A%2Faethlonmedical.com%2F___.YXAzOmFldGhsb246YTpvOmI3YWI2N2Q2OWRiZjI1MjAzMDg1MWYzYTRmNWQ4YjYxOjY6NjNiYTpmNzBkM2E2YjIwNTc2MDI1ZjRlZmJiMWVmMzQ5Mzg2MDJmMjk4M2EwZTcwOGM5NDUyOTJiNTY1NWFlNjFlYzhhOnA6VDpO&amp;a=Aethlon+Medical%2C+Inc.">Aethlon Medical, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the publication (<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4426889-1&amp;h=1501579374&amp;u=https%3A%2F%2Fnam10.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Furl.avanan.click%252Fv2%252Fr01%252F___https%253A%252F%252Fwww.biorxiv.org%252Fcgi%252Fcontent%252Fshort%252F2025.05.09.652772v1___.YXAzOmFldGhsb246YTpvOmNkYzRhZTdkMWI3ZTUxNWI5ZDExYjhiZWIwOTRjODg1Ojc6ZDIxMjozNjNjZmJiYzAxMTExYmVmMTNiZWQwZmExYzZhNmUwN2UyNzhmZjAyMjVjNzY4MGIyNDIzNDMzOTE0NzI0YWMxOmg6VDpO%26data%3D05%257C02%257Cjfrakes%2540aethlonmedical.com%257Cd4c75a54908d4f56752608dd915c03b8%257Cb05c6cbde2e7484591da08f8877ed463%257C0%257C0%257C638826546585994320%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C0%257C%257C%257C%26sdata%3DnhdDJmeJjBT1qKRv%252BGGZU9FPRGjQ8IeyjEtFvdP8QWI%253D%26reserved%3D0&amp;a=https%3A%2F%2Fwww.biorxiv.org%2Fcgi%2Fcontent%2Fshort%2F2025.05.09.652772v1">https://www.biorxiv.org/cgi/content/short/2025.05.09.652772v1</a>) of a pre-clinical ex vivo study in pre-print vehicle bioRxiv, entitled, "Ex Vivo Removal of CD41 positive platelet microparticles from Plasma by a Medical Device containing a Galanthus nivalis agglutinin (GNA) affinity resin."
Aethlon Medical's Hemopurifier&#xAE; is a therapeutic blood filtration system designed to bind and remove harmful extracellular vesicles (EVs or exosomes) and life-threatening viruses from blood and other biological fluids, properties that support its evaluation not only in oncology and infectious diseases, but also in the organ transplantation and other areas of significant unmet medical need.
Platelet-derived extracellular vesicles (PD-EVs) are the most numerous EV population in the body and are released by platelets in response to a variety of stimuli. The cargo contained within these EVs have been noted to participate in damage to blood vessels, activation of immune cells, and spread of tumor cells. Excessive levels of PD-EVs have been implicated in a myriad of diseases, including cancer, lupus, systemic sclerosis, multiple sclerosis, Alzheimer's disease, sepsis, acute and Long COVID.
An independent research team had demonstrated that PD-EVs in Alzheimer's patients bound to the plant lectin Galanthus nivalis agglutinin (GNA). We hypothesized that the Aethlon Hemopurifier, which contains a proprietary GNA affinity resin would remove platelet derived EVs from plasma. In this experiment two hundred milliliters of donated healthy human plasma were circulated over the Aethlon Hemoupurifier (HP) to simulate a clinical HP session. The study results indicated a 98.5% removal of platelet -derived EVs at a timepoint equivalent to a 4-hour HP treatment.

News

AEMD

Aethlon Medical Publishes Preclinical Data Showing Ability Of Hemopurifier To Remove Platelet-Derived Extracellular Vesicles From Plasma

WIIM

OVID

Ovid Therapeutics shares are trading higher after the company reported better-than-expected Q1 sales results.

Loop Capital analyst Laura Champine downgrades Wayfair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) from Hold to Sell and announces $35 price target.

Downgrades

Price Target

Analyst Ratings

Loop Capital Downgrades Wayfair to Sell, Announces $35 Price Target

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is consolidating near record levels while altcoins show significant momentum, according to cryptocurrency analyst Michaël van de Poppe.
What Happened: &#8220;A pretty normal consolidation on Bitcoin before the breakout above the all-time high,&#8221; van de Poppe wrote Wednesday on X. &#8220;In the meantime, altcoins are significantly breaking out and continuing their momentum. The signs of a bull market.&#8221;
The leading cryptocurrency is trading at $104,030.18, up 0.25% over the past 24 hours, with a total market capitalization of $2.06 trillion. Meanwhile, Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) has gained 4.42%, reaching $2,625.37 with a market cap of $316.95 billion.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">A pretty normal consolidation on <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> before the breakout above the all-time high. In the meantime; <a href="https://twitter.com/hashtag/Altcoins?src=hash&amp;ref_src=twsrc%5Etfw">#Altcoins</a> are significantly breaking out and continuing their momentum. The signs of a bull market. <a href="https://t.co/GCPuPsGkjg">pic.twitter.com/GCPuPsGkjg</a>
&mdash; Michaël van de Poppe (@CryptoMichNL) <a href="https://twitter.com/CryptoMichNL/status/1922546272197582942?ref_src=twsrc%5Etfw">May 14, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Van de Poppe noted correlations between traditional and crypto markets, stating: &#8220;Renminbi keeps grinding higher &#8211;&gt; ETH keeps grinding higher.&#8221; He added that Bitcoin is approaching a new all-time high &#8220;in the coming 1-2 weeks&#8221; while Ethereum outperforms.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Renminbi keeps grinding higher &#8211;&gt; <a href="https://twitter.com/search?q=%24ETH&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$ETH</a> keeps grinding higher. Generally glad to see that <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> is approaching a new all-time high in the coming 1-2 weeks and Ethereum outperforms.
&mdash; Michaël van de Poppe (@CryptoMichNL) <a href="https://twitter.com/CryptoMichNL/status/1922402723242160628?ref_src=twsrc%5Etfw">May 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/25/05/45396450/bitcoin-ethereum-dogecoin-pop-on-softer-inflation-analyst-says-cocktail-for-bitcoins-ballistic-rise-was-in-the-works">Bitcoin, Ethereum, Dogecoin Pop As Inflation Numbers Softer Despite Trump Tariffs: Analyst Says Cocktail For BTC&#8217;s &#8216;Ballistic&#8217; Rise In The Works</a>
Why It Matters: The CMC Altcoin Season Index, which measures whether the market favors Bitcoin or alternative cryptocurrencies, currently reads 30/100, indicating the market remains in &#8220;Bitcoin Season.&#8221; The index considers the top 100 coins&#8217; performance relative to Bitcoin over 90 days, according to <a href="https://coinmarketcap.com/charts/altcoin-season-index/">data</a> from CoinMarketCap.
Several altcoins have significantly outperformed Bitcoin in recent months, with FORM up over 206.68%, FARTCOIN rising 183.56%, and IP gaining 149.35%. Other notable performers include Maker, up 91.12%, and Monero, which has increased by 52.58%.
This consolidation period comes as inflation data has been softer than expected, creating what van de Poppe recently described as &#8220;the cocktail for Bitcoin to go ballistic.&#8221; 
Bitcoin IRA co-founder Chris Kline <a href="https://www.benzinga.com/25/05/45396450/bitcoin-ethereum-dogecoin-pop-on-softer-inflation-analyst-says-cocktail-for-bitcoins-ballistic-rise-was-in-the-works">attributes Bitcoin&#8217;s strong performance</a> partly to &#8220;the strategic reserve race among states,&#8221; creating &#8220;unprecedented demand pressure against Bitcoin&#8217;s mathematically limited supply.&#8221;
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/tech/25/05/45401165/tesla-gears-up-to-restart-key-component-shipping-from-china-for-cybercab-semi-truck-production-in-us-report">Tesla Gears Up To Restart Key Component Shipping From China For Cybercab, Semi Truck Production In US: Report</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$BTC

$ETH

Bitcoin Consolidates Before All-Time High Breakout As Altcoins Surge — 'Signs Of A Bull Market,' Says Michaël Van De Poppe

ADC Therapeutics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.40) by 45 percent. This is a 42.11 percent increase over losses of $(0.38) per share from the same period last year. The company reported quarterly sales of $23.03 million which beat the analyst consensus estimate of $17.71 million by 30.05 percent. This is a 27.57 percent increase over sales of $18.05 million the same period last year.

Earnings

Earnings Beats

ADCT

ADC Therapeutics Q1 Adj. EPS $(0.22) Beats $(0.40) Estimate, Sales $23.03M Beat $17.71M Estimate

KTTA

Pasithea Therapeutics shares are trading higher after the company announced initiation of its Phase 1/1b open label study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PAS-004, in adult participants with neurofibromatosis type 1 with symptomatic and inoperable, incompletely resected, or recurrent plexiform neurofibromas.

Editor&#8217;s Note: This story has been updated to include the latest data.
U.S. stock futures reversed early losses to trade in the green during Wednesday's premarket session, following a mixed finish on Tuesday. The S&amp;P 500 and Nasdaq 100 indices turned positive for the year after Tuesday&#8217;s advance.
A positive inflation report for April and easing trade concerns boosted investor sentiment, but the tech sector&#8217;s gains were largely driven by chipmaker Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>). The company&#8217;s stock soared thanks to both an expected overhaul of chip regulations and a new collaboration with <a href="https://www.benzinga.com/markets/equities/25/05/45398595/trump-praises-nvidia-ceo-jensen-huang-at-saudi-summit-tim-cook-isnt-here-but-you-are-controlling-99-of-the-chip-market-thats-not-easy-to-beat">Saudi Arabia</a>. 
The 10-year Treasury bond yielded 4.45% and the two-year bond was at 3.99%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool&#8217;s </a>projections show markets pricing a 91.8% likelihood of the Federal Reserve keeping the current interest rates unchanged in its June meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.05%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.22%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.36%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.08%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were trading higher in premarket on Wednesday. The SPY was up 0.22% to $588.11, while the QQQ advanced 0.37% to $517.48, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
Information technology, consumer discretionary, energy and communication services sectors saw the biggest gains on Tuesday. Whereas health care, consumer staples, and real estate sectors declined. 
The Labor Department&#8217;s Tuesday report showed a 2.3% year-over-year rise in the Consumer Price Index for April, below the 2.4% economist expectation, while core CPI&#8217;s 2.8% increase matched estimates.
After Tuesday, the S&amp;P 500 index turned positive for the year, up 0.31% year-to-date. Meanwhile, Dow Jones was still down -0.59% YTD, and Nasdaq 100 was up 1.06%.
The Dow Jones index declined 270 points or 0.64% to 42,140.43, whereas the S&amp;P 500 index rose 0.72% to 5,886.55. Nasdaq Composite ended 1.61% higher at 19,010.08, and the small-cap gauge, Russell 2000, climbed 0.49% to 2,102.35.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>1.61%</td>
<td>19,010.08</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.72%</td>
<td>5,886.55</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.64%</td>
<td>42,140.43</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.49%</td>
<td>2,102.35</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
According to Ryan Detrick, chief market strategist for the Carson Group, a recent market observation is signaling <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45394972/sp-500-turns-positive-on-the-year-flashes-quite-rare-and-rather-bullish-signal">potential for further gains</a>. 
Detrick noted that on Tuesday, over 60% of the S&amp;P 500 components reached new 20-day highs, highlighting the historical bullish implications of this infrequent event.
As Detrick stated in a post on X, &#8220;This is quite rare and rather bullish. Strong performance across the board and higher a year later 18 out of 18 times.&#8221;
The market is flashing another bullish signal that could indicate even more gains ahead, according to Ryan Detrick, chief market strategist for the Carson Group.
Detrick observed that on Tuesday, more than 60% of the components in the S&amp;P 500 are hitting new 20-day highs and pointed to a historically bullish year following this rare occurrence.
&#8220;This is quite rare and rather bullish. Strong performance across the board and higher a year later 18 out of 18 times,&#8221; Detrick wrote in a post on X.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">After today we will have more than 60% of the components in the S&amp;P 500 hitting a new 20-day high. This is quite rare and rather bullish. Strong performance across the board and higher a year later 18 out of 18 times. &#x1f4aa; <a href="https://t.co/0D4Pm0scqS">pic.twitter.com/0D4Pm0scqS</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1922361671332303080?ref_src=twsrc%5Etfw">May 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Wharton Professor of Finance and WisdomTree Senior Economist Jeremy Siegel <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45389778/jeremy-siegel-calls-us-china-deal-amazing-expects-long-term-stability">expressed significant optimism</a> regarding the recently announced U.S.-China trade deal, stating it was &#8220;a lot better than anyone was anticipating,&#8221; and predicting it will &#8220;stay that way.&#8221; 
Speaking on CNBC's "Squawk On The Street" on Tuesday, Siegel described it as an "amazing" deal benefiting all, including market participants.
He noted, "There was no analyst out there that predicted that we'd come to an agreement — at least a tentative agreement — so quickly, and actually specify tariff levels as low as they came in. It was like, wow, this is great news."
Siegel pointed out that with previous forecasts from Trump suggesting tariff reductions to the 50% to 80% range, the 30% announcement surprised markets and triggered a substantial rally. He further told CNBC that he expects the agreement to endure, stating he doesn't believe the two major economies will reimpose higher tariffs as trade tensions have "settled down."
While acknowledging potential "small adjustments" and that tariffs won't have "zero effect" given the current 17% average tariff for U.S. consumers (the highest in 85 years), Siegel said, "But it's certainly going to have a lot less effect than what it seemed like just a week ago."
The economist anticipates a likely increase in inflation in June or July due to tariff impacts on earnings and growth, but doesn&#8217;t foresee this lasting long-term.
He suggested that the Fed should cut rates if conditions worsen and then raise them if they improve, contrasting this with the common expectation of a rate-cutting cycle and the Fed&#8217;s emphasis on data dependence.
Siegel believes this approach is flawed, noting that while near-term inflation could rise due to supply shocks, long-term indicators appear stable. Finally, he observed, "The good news is that the tone of Trump is so much different now than it was two or three months ago," hinting at the possibility of more trade agreements in the future.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Wednesday:
<ul class="wp-block-list">
<li>Fed Governor Christopher Waller will speak at 5:15 a.m., Fed Vice Chair Philip Jefferson will speak at 9:10 a.m., and San Francisco Fed President Mary Daly will speak at 5:40 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul class="wp-block-list">
<li>American Eagle Outfitters Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) dropped 14.47% in premarket on Wednesday after it reported preliminary results for the first quarter and withdrew its full-year guidance.</li>
</ul>
<ul class="wp-block-list">
<li>Cisco Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) was up 0.15% as analysts expect the San Jose, California-based company to report quarterly earnings at 92 cents per share, up from 88 cents per share in the year-ago period, after the closing bell.</li>
</ul>
<ul class="wp-block-list">
<li>Endava PLC ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAVA#NYSE">DAVA</a>) jumped 5.09% as it is expected to report before the opening bell. Analysts expect the U.K.-based company to report quarterly earnings at 31 cents per share, compared to 22 cents per share in the year-ago period.</li>
</ul>
<ul class="wp-block-list">
<li>Dynatrace Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) advanced 1.78% as analysts expect the Waltham, Massachusetts-based company to report quarterly earnings at 30 cents per share, compared to 30 cents per share in the year-ago period. The results will be announced before the opening bell.</li>
</ul>
<ul class="wp-block-list">
<li>Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) was up 1.90%, continuing the momentum after reports that the United Arab Emirates may receive approval to purchase over a million of its advanced AI processors, while Saudi Arabia pledged up to $600 billion in future U.S. investments, with a focus on technology and infrastructure.</li>
</ul>
<ul class="wp-block-list">
<li>Innovative Eyewear Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) zoomed 48.99% after its first-quarter revenue reached $454,501, up 19% year-on-year, driven by new product launches, including Nautica and Eddie Bauer collections.</li>
</ul>
<ul class="wp-block-list">
<li>Actelis Networks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASNS#NASDAQ">ASNS</a>) slumped 16.25% after it reported a quarterly loss of $0.22 per share and also posted revenue of $0.72 million, missing estimates during the first quarter.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 1.35% to hover around $62.81 per barrel.
Gold Spot US Dollar fell 0.53% to hover around $3,233.05 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index spot was lower by 0.62% at the 100.3810 level.
Asian markets ended higher on Wednesday except Japan's Nikkei 225 index. India's S&amp;P BSE Sensex, Hong Kong's Hang Seng, South Korea's Kospi, China&#8217;s CSI 300, and Australia's ASX 200 indices advanced. European markets were mostly lower in early trade.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/market-summary/25/05/45399940/warren-buffett-shows-how-patience-pays-98-of-his-160-billion-wealth-came-after-turning-65-thanks-the-power-of-compound-interest">Warren Buffett Shows How Patience Pays: 98% Of His $160 Billion Wealth Came After Turning 65, Thanks The Power Of &#8216;Compound Interest&#8217;</a></li>
</ul>
Image Via Shutterstock

Analyst Color

Asia

Earnings Misses

Equities

Government

Macro Economic Events

Macro Notification

Market Summary

Regulations

Bonds

Broad U.S. Equity ETFs

Guidance

Emerging Markets

Eurozone

Futures

Commodities

Forex

Treasuries

Federal Reserve

Pre-Market Outlook

ETFs

General

ASNS

CSCO

DAVA

KDLY

LUCY

NVDA

US Stock Futures Trade Higher On Wednesday: S&P 500 Is Flashing 'Quite Rare And Rather Bullish' Signal, Says Expert (UPDATED)

LUCD

Lucid Diagnostics Q1 Adj. EPS $(0.16), Inline, Sales $800.00K Miss $1.28M Estimate

Revolution Medicines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVMD#NASDAQ">RVMD</a>), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient has been dosed in RASolve 301, a global, randomized, open-label Phase 3 clinical trial. RASolve 301 will evaluate the safety and efficacy of daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor, in patients with previously treated, locally advanced or metastatic RAS mutant non-small cell lung cancer (NSCLC) compared to docetaxel chemotherapy.

RVMD

Revolution Medicines Announces First Patient Dosed In Phase 3 Clinical Trial, RASolve 301

Dividends

Buybacks

Curtiss-Wright Announces $400M Increase In Share Repurchase Authorization, Increases Dividend From $0.21 To $0.24 Per Share

RDCM

Radcom shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results and raised its FY25 sales guidance above estimates.

Barclays analyst Benjamin Theurer downgrades Lavoro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVRO#NASDAQ">LVRO</a>) from Overweight to Underweight and lowers the price target from $5 to $1.5.

LVRO

Barclays Downgrades Lavoro to Underweight, Lowers Price Target to $1.5

Details of the FDA's minutes include the following, all of which will be a matter of review during the approval process:
<ul>
<li>The agency agreed to a post-NDA approval commitment of additional stability date for the 6 intermediate dose strengths of 12.5-mg, 18.75-mg, 25-mg, 31.25-mg, 37.5-mg, and 43.75-mg.</li>
<li>Cingulate expects shelf-life for all dosage strengths to be 24 months at launch, the results from the aforementioned batches may allow the shelf-life to be extended.</li>
<li>Available data for nonclinical safety appears adequate to support a filing.</li>
<li>With a scientific bridge established upon review, CTx-1301 may rely on the efficacy and safety data of the listed drug, Focalin XR.</li>
<li>Cingulate's proposed approach to the integrated safety summary (ISS) and integrated summary of efficacy (ISE) appears reasonable.</li>
</ul>

CING

Cingulate Receives Formal Pre-NDA Meeting Minutes From FDA For CTx-1301 In ADHD

Franklin Street Properties shares are trading higher after the company announced it initiated a review of strategic alternatives.

LiqTech International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIQT#NASDAQ">LIQT</a>) sees Q2 sales of $4.800 million-$5.200 million vs $4.70 million analyst estimate.

LIQT

LiqTech International Sees Q2 Sales $4.800M-$5.200M vs $4.70M Est

Sow Good (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOWG#NASDAQ">SOWG</a>) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.11) by 109.09 percent. This is a 483.33 percent decrease over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $2.48 million which missed the analyst consensus estimate of $6.50 million by 61.89 percent. This is a 78.28 percent decrease over sales of $11.41 million the same period last year.

SOWG

Sow Good Q1 GAAP EPS $(0.23) Misses $(0.11) Estimate, Sales $2.48M Miss $6.50M Estimate

Ratings for Rigetti Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $15.0, a high estimate of $17.00, and a low estimate of $14.00. Marking an increase of 27.12%, the current average surpasses the previous average price target of $11.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1747224119_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Rigetti Computing's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>David Williams</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>David Williams</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$14.00</td>
<td>$2.50</td>
</tr>
<tr>
<td>Craig Ellis</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$8.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Rigetti Computing. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Rigetti Computing compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Rigetti Computing's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Rigetti Computing's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RGTI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Rigetti Computing analyst ratings.</a>
<h2>Get to Know Rigetti Computing Better</h2>
Rigetti Computing Inc is engaged in the business of full-stack quantum computing. The company offers full-stack quantum computing platform as a cloud service to a wide range of end-users, directly through its Rigetti QCS platform, and also through cloud service providers. Its proprietary quantum-classical infrastructure provides ultra-low latency integration with public and private clouds for high-performance practical quantum computing. The company has developed the industry's first multi-chip quantum processor for scalable quantum computing systems. Geographically, the company derives the majority of its revenue from the United States.
<h3>Rigetti Computing's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Decline in Revenue: Over the 3M period, Rigetti Computing faced challenges, resulting in a decline of approximately -32.64% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Rigetti Computing's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -6726.52%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Rigetti Computing's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -122.65%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Rigetti Computing's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -69.21%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Rigetti Computing's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.07.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RGTI

Deep Dive Into Rigetti Computing Stock: Analyst Perspectives (5 Ratings)

RANI

Rani Therapeutics Holdings shares are trading higher. The company reported Q1 financial results.

Silicon Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLAB#NASDAQ">SLAB</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $136.67, a high estimate of $160.00, and a low estimate of $80.00. Experiencing a 7.34% decline, the current average is now lower than the previous average price target of $147.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1747224095_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Silicon Laboratories. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$150.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Blayne Curtis</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$80.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Tore Svanberg</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$120.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$150.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Silicon Laboratories. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Silicon Laboratories compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Silicon Laboratories's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Silicon Laboratories's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SLAB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Silicon Laboratories analyst ratings.</a>
<h2>About Silicon Laboratories</h2>
Silicon Laboratories Inc Inc is a provider of secure, intelligent wireless technology for a more connected world. The company's integrated hardware and software platform, intuitive development tools, industry ecosystem, and robust support help customers build industrial, commercial, home, and life applications. Company make it easy for developers to solve complex wireless challenges throughout the product lifecycle and get to market quickly with solutions that transform industries, grow economies, and improve lives. Company operates in USA, China, Taiwan and Rest of World, with maximum revenue from rest of the world.
<h3>Silicon Laboratories: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Silicon Laboratories's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 91.43%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -14.33%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Silicon Laboratories's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -2.2%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Silicon Laboratories's ROA excels beyond industry benchmarks, reaching -1.93%. This signifies efficient management of assets and strong financial health.
Debt Management: Silicon Laboratories's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SLAB

The Analyst Verdict: Silicon Laboratories In The Eyes Of 6 Experts

LiqTech Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIQT#NASDAQ">LIQT</a>) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.18) by 38.89 percent. This is a 24.24 percent increase over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $4.62 million which beat the analyst consensus estimate of $4.50 million by 2.62 percent. This is a 9.04 percent increase over sales of $4.24 million the same period last year.

LiqTech Intl Q1 EPS $(0.25) Misses $(0.18) Estimate, Sales $4.62M Beat $4.50M Estimate

Comments

Global X DAX Germany ETF

空売り

Global X DAX Germany ETF (NASDAQ:DAX), 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル